Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: Association with tumor progression

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 4, 2014, Pages 426-432

  Debiais Delpech, Celine ^a   Godet, Julie ^a   Pedretti, Nathalie ^b   Bernard, François Xavier ^b   Irani, Jacques ^a   Cathelineau, Xavier ^c   Cussenot, Olivier ^d   Fromont, Gaelle ^a,d  

^a UNIVERSITÉ DE POITIERS   (France)

^b Department of Molecular Biology Bioalternatives ^*  (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Candidate gene analysis; CtBP2; HNF1 transcription factor; Immunohistochemistry; Prostate cancer; RT PCR

Indexed keywords

BINDING PROTEIN; CTBP2 PROTEIN; GONADORELIN AGONIST; HEPATOCYTE NUCLEAR FACTOR 1BETA; MESSENGER RNA; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; CTBP2 PROTEIN, HUMAN; HNF1B PROTEIN, HUMAN; NERVE PROTEIN; TUMOR MARKER;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; FROZEN SECTION; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCALIZED PROSTATE CANCER; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; TUMOR GROWTH; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; DNA MICROARRAY; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ALCOHOL OXIDOREDUCTASES; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84899471666     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.006     Document Type: Article

References (25)

1. Liu H., Wang B., Han C. Meta-analysis of genome-wide and replication association studies on prostate cancer. Prostate 2011, 71:209-224.
2. Thomas G., Jacobs K.B., Yeager M., et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008, 40:310-315.
3. Waters K.M., Le Marchand L., Kolonel L.N., et al. Generalizability of associations from prostate cancer GWAS in multiple populations. Cancer Epidemiol Biomarkers Prev 2009, 18:1285-1289.
4. Sun J., Zheng S.L., Wiklund F., et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008, 40:1153-1155.
5. Eeles R.A., Kote-Jarai Z., Giles G.G., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40:316-321.
6. Grisanzio C., Werner L., Takeda D., et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A 2012, 109:11252-11257.
7. Whitaker H.C., Kote-Jarai Z., Ross-Adams H., et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One 2010, 5:e13363.
8. Fromont G., Rozet F., Cathelineau X., et al. BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy. Prostate 2012, 72:1359-1365.
9. Fromont G., Godet J., Peyret A., et al. 8q24 amplification is associated with MYC expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Human Pathol 2013, [Epub ahead of print].
10. Ahn J., Kibel A.S., Park J.Y., et al. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res 2011, 17:1075-1081.
11. Bensen J.T., Xu Z., Smith G.J., Mohler J.L., Fontham E.T., Taylor J.A. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate 2013, 73:11-22.
12. Xu B., Wang J.F., Tong N., et al. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate 2010, 70:1146-1152.
13. Dahlman A., Rexhepaj E., Brennan D.J., et al. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol 2011, 24:708-719.
14. Dahlman A., Edsjo A., Hallden C., et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis 2010, 13:369-375.
15. Shukeir N., Arakelian A., Chen G., et al. A synthetic 15-mer Peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 2004, 64:5370-5377.
16. Lamy S., Ruiz M.T., Wisniewski J., et al. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer 2006, 118:2350-2358.
17. Tsuchiya A., Sakamoto M., Yasuda J., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-2512.
18. Harries L.W., Perry J., McCullagh P., Crundwell M. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 2010, 10:315-326.
19. Senkel S., Lucas B., Klein-Hitpass L., Ryffel G.U. Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line. Biochim Biophys Acta 2005, 1731:179-190.
20. Castellano G., Malaponte G., Mazzarino M.C., et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008, 14:7470-7480.
21. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 2009, 69:731-734.
22. Straza M.W., Paliwal S., Kovi R.C., et al. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle 2010, 9:3740-3746.
23. Birts C.N., Harding R., Soosaipillai G., et al. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance. Biol Cell 2011, 103:1-19.
24. Verger A., Quinlan K.G.R., Crofts L.A., et al. Mechanisms directing the nuclear localization of the CtBP family proteins. Mol Cell Biol 2006, 26:4882-4893.
25. Paliwal S., Ho N., Parker D., Grossman S.R. CtBP2 promotes human cancer cell migration by transcriptional activation of Tiam1. Genes and Cancer 2012, 3:481-490.